Skip to main content
Terug
AZN logo

AstraZeneca PLC

Datakwaliteit: 100%
AZN
NYSE Healthcare Drug Manufacturers - General
€ 185,78
▲ € 1,71 (0,93%)
Marktkapitalisatie: 144,01B
Dagbereik
€ 182,39 € 186,22
52-Weeksbereik
€ 122,48 € 212,71
Volume
1.574.520
50D / 200D Gem.
€ 193,92 / € 169,71
Vorige Slotkoers
€ 184,07

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 14,0 0,3
P/B 3,0 2,9
ROE % 22,9 3,7
Net Margin % 17,5 3,8
Rev Growth 5Y % 11,9 10,0
D/E 0,6 0,2

Koersdoel Analisten

Hold
€ 105,50 -43.2%
Low: € 103,00 High: € 108,00
Forward K/W
17,9
Forward WPA
€ 10,30
WPA Groei (sch.)
+0,0%
Omzet Sch.
63 B

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 16,10
€ 15,11 – € 16,73
 81 B 5
FY2029 € 14,41
€ 13,52 – € 14,97
 76 B 2
FY2028 € 12,93
€ 9,59 – € 14,37
 71 B 7

Belangrijkste Punten

Revenue grew 11,93% annually over 5 years — strong growth
Earnings grew 45,77% over the past year
ROE of 22,93% indicates high profitability
Net margin of 17,46% shows strong profitability
Generating 11,77B in free cash flow
P/E of 14,04 — trading at a low valuation

Groei

Revenue Growth (5Y)
11,93%
Revenue (1Y)8,63%
Earnings (1Y)45,77%
FCF Growth (3Y)33,85%

Kwaliteit

Return on Equity
22,93%
ROIC13,15%
Net Margin17,46%
Op. Margin23,40%

Veiligheid

Debt / Equity
0,61
Current Ratio0,94
Interest Coverage8,11

Waardering

P/E Ratio
14,04
P/B Ratio2,96
EV/EBITDA12,22
Dividend Yield0,04%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 8,63% Revenue Growth (3Y) 13,23%
Earnings Growth (1Y) 45,77% Earnings Growth (3Y) 31,23%
Revenue Growth (5Y) 11,93% Earnings Growth (5Y) 209,34%
Profitability
Revenue (TTM) 58,74B Net Income (TTM) 10,26B
ROE 22,93% ROA 8,99%
Gross Margin 81,90% Operating Margin 23,40%
Net Margin 17,46% Free Cash Flow (TTM) 11,77B
ROIC 13,15% FCF Growth (3Y) 33,85%
Safety
Debt / Equity 0,61 Current Ratio 0,94
Interest Coverage 8,11 Dividend Yield 0,04%
Valuation
P/E Ratio 14,04 P/B Ratio 2,96
P/S Ratio 2,45 PEG Ratio 0,07
EV/EBITDA 12,22 Dividend Yield 0,04%
Market Cap 144,01B Enterprise Value 168,00B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 58,74B 54,07B 45,81B 44,35B 37,42B
Net Income 10,26B 7,04B 5,96B 3,29B 112,00M
EPS (Diluted) 13,08 4,50 7,62 4,22 0,16
Gross Profit 48,11B 43,87B 37,54B 31,96B 24,98B
Operating Income 13,74B 10,00B 8,19B 3,76B 1,06B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 114,07B 104,04B 101,12B 96,48B 105,36B
Total Liabilities 65,36B 63,16B 61,95B 59,43B 66,08B
Shareholders' Equity 48,67B 40,79B 39,14B 37,04B 39,27B
Total Debt 29,70B 30,11B 28,62B 29,14B 30,69B
Cash & Equivalents 5,71B 5,49B 5,84B 6,17B 6,33B
Current Assets 28,72B 25,83B 25,05B 22,59B 26,24B
Current Liabilities 30,62B 27,87B 30,54B 26,29B 22,59B

Strategiescores

This stock passed the criteria for 5 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#305 of 1052
55
Custom Capital Light Compounder
#137 of 218
35
Growth + Value Growth at a Reasonable Price (Peter Lynch)
#264 of 332
38
Custom Balanced Risk
#60 of 151
48
Custom Lower Risk
#71 of 140
45

Recente Activiteit

Ingestapt Cash Flow Compounder
Mar 24, 2026
Ingestapt Capital Light Compounder
Mar 24, 2026
Ingestapt Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026
Ingestapt Balanced Risk
Mar 24, 2026
Ingestapt Lower Risk
Mar 24, 2026